Patent intelligence · EP
EP 3964220
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE
Patent details — EP 3964220
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Mar 9, 2022
- Expiration
- Mar 4, 2042
- Applicant
- BIOCODEX [FR]
- CPC classes
- A61K 36/ 064 A I, A61K/36064, A61P 19/ 00 A I, A61P 19/ 08 A I
Quick answer
EP 3964220 (PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE) is held by BIOCODEX [FR]. Status: granted. Granted Mar 9, 2022. Expires Mar 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOCODEX [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 36/ 064 A I, A61K/36064, A61P 19/ 00 A I, A61P 19/ 08 A I, A61P 19/ 10 A I, A61P/1900
More from BIOCODEX [FR]
Related pharmaceutical patents in our USPTO index.
-
WO 2026013310
COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL
granted -
WO 2024194388
PREPARATION DE LEVURE SACCHAROMYCES BOULARDII INACTIVEE
granted -
WO 2023046844
COMPOSITIONS PHARMACEUTIQUES UTILES POUR LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS VIRALES
granted -
FR 3121841
Traitement des hyperammoniémies
granted -
EP 3485879
ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN
granted -
CA 3072544
SACCHAROMYCES BOULARDII POUR LE TRAITEMENT DES TROUBLES DE L'HUMEUR
granted -
CA 3065417
TRAITEMENT DE MALADIES ASSOCIEES A UNE DYSREGULATION DE LA VOIE MTOR
granted
Frequently asked questions
What is US patent 3964220?
EP 3964220 (PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE) is held by BIOCODEX [FR]. Status: granted. Granted Mar 9, 2022. Expires Mar 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3964220?
BIOCODEX [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 3964220 expire?
Our index shows an expiration date of Mar 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.